PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five
Years Involving 175,000 Patients Worldwide

BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation
(Nasdaq: PRXL), a leading global biopharmaceutical services provider, today
announced it has reached a milestone in managing oncology-based clinical
trials over the last five years, which have involved over 175,000 patients in
hundreds of programs across 80 countries. PAREXEL will be marking this
milestone during the American Society of Clinical Oncology (ASCO) Annual
Meeting, to be held May 29 - June 2, 2009 in Orlando, Florida. PAREXEL's
hematology and oncology experts will be available during the ASCO meeting at
Booth #1980 to discuss their capabilities to support the successful
development of novel cancer treatments.

"Significant advances in targeted therapies for cancer have generated more
competition for patient populations. To meet industry demand for conducting
cancer trials across a broad range of indications, PAREXEL continues to
leverage our global footprint and ability to manage complex programs on a
worldwide scale to help biopharmaceutical companies access diverse patient
populations, navigate regulatory issues, and identify effective
investigators," said Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL
International.

"With approximately 10 million people diagnosed with cancer each year
worldwide, PAREXEL works with biopharmaceutical companies toward the goals of
improving the development success rate for oncology drugs and getting
treatments to patients sooner," said Denis R. Miller, M.D., Senior Medical
Director, Clinical Research Services, PAREXEL. "Our global team of hematology
and oncology experts helps clients advance important innovations through our
understanding of unmet medical needs, the standards of available cancer care
worldwide, and how new anticancer agents will be positioned in the treatment
of patients, from the earliest phases of clinical development through the
approval process and into post-marketing."

PAREXEL has experience across a broad range of cancer indications as well as
all classes of therapeutics including cytotoxics, biologics, targeted
therapies, immunotherapies, vaccine therapies, and supportive treatments, such
as blood products, growth factors, antiemetics, and analgesics. PAREXEL's
Hematology/Oncology Therapeutic Area Team offers expertise to help clients
with every facet of drug development, including protocol review, safety
assessment, clinical development, medical imaging, technology integration,
regulatory affairs, and product lifecycle management. Comprehensive services
provided by the team include the planning, design, and management of
feasibility studies, Phase I - IV trials, and post-marketing studies as well
as site selection, patient recruitment, data analysis, non-clinical
evaluation, and IND/NDA submissions. PAREXEL leverages the experience and
relationships its experts have with leading cancer centers and key opinion
leaders in its ongoing collaborative efforts.

PAREXEL applies a proven, therapeutically focused expertise methodology to
clinical development programs across a broad range of areas. For more
information about PAREXEL's in-depth expertise in the oncology, central
nervous system (CNS), cardiovascular, infectious disease therapeutic areas, as
well as a broad range of other therapeutic areas, visit:
http://www.parexel.com/clinical_research/therapeutic_expertise.html.

Information about the ASCO Annual Meeting can be found at:
http://www.asco.org/annualmeeting.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based contract
research, medical communications and consulting services to the worldwide
pharmaceutical, biotechnology and medical device industries. Committed to
providing solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development and
commercialization continuum, from drug development and regulatory consulting
to clinical pharmacology, clinical trials management, medical education and
reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides
advanced technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston, Massachusetts,
PAREXEL operates in 69 locations throughout 52 countries around the world, and
has over 9,400 employees. For more information about PAREXEL International
visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results
and events. For this purpose, any statements contained herein that are not
statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "intends," "appears," "estimates," "projects," "targets," and
similar expressions are also intended to identify forward-looking statements.
The forward-looking statements in this release involve a number of risks and
uncertainties. The Company's actual future results may differ significantly
from the results discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference include, but are
not limited to, risks associated with: actual operating performance; actual
expense savings and other operating improvements resulting from recent
restructurings; the loss, modification, or delay of contracts which would,
among other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries and
clients; the Company's ability to win new business, manage growth and costs,
and attract and retain employees; the Company's ability to complete additional
acquisitions and to integrate newly acquired businesses or enter into new
lines of business, including, but not limited to, the successful business
integration and anticipated synergy achievements in connection with the
ClinPhone acquisition; the impact on the Company's business of government
regulation of the drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant liability
to clients and third parties; the potential adverse impact of health care
reform; and the effects of exchange rate fluctuations and other international
economic, political, and other risks. Such factors and others are discussed
more fully in the section entitled "Risk Factors" of the Company's Quarterly
Report on Form 10-Q for the quarter ended March 31, 2009 as filed with the SEC
on May 8, 2009, which "Risk Factors" discussion is incorporated by reference
in this press release. The forward-looking statements included in this press
release represent the Company's estimates as of the date of this release. The
Company specifically disclaims any obligation to update these forward-looking
statements in the future. These forward-looking statements should not be
relied upon as representing the Company's estimates or views as of any date
subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and
Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All
other names or marks may be registered trademarks or trademarks of PAREXEL
International Corporation, Perceptive Informatics, Inc. or their respective
owners and are hereby acknowledged.

Contacts:
Jennifer Baird, Senior Director of Public Relations
PAREXEL International
Tel: +781-434-4409
Email: Jennifer.Baird@PAREXEL.com

Rebecca Passo
SHIFT Communications
Tel: +617-779-1817
Email: rpasso@shiftcomm.com

SOURCE PAREXEL International Corporation

Jennifer Baird, Senior Director of Public Relations of PAREXEL International,
+1-781-434-4409, Jennifer.Baird@PAREXEL.com; or Rebecca Passo of SHIFT
Communications for PAREXEL, +1-617-779-1817, rpasso@shiftcomm.com